Table 3.

Correlations between tumour necrosis percentage and serum cytokine levels.

	Cohort 2A (2006–January 2010)					Cohort 2B (February 2010–2014)
Variable	N (unadjusted, adjusted)	Unadjusted		Adjusted		N (unadjusted, adjusted)	Unadjusted		Adjusted
		Pearson r	P value	Beta	P value		Pearson r	P value	Beta	P value
IL1RN	117, 116	0.091	0.33	−0.003	0.97	–a	–	–	–	–
IL4	117, 116	0.073	0.43	0.063	0.50	–a	–	–	–	–
IL6	117, 116	0.245	0.008	0.191	0.043	–b	–	–	–	–
IL7	117, 116	0.121	0.19	0.083	0.38	150, 150	0.242	0.003	0.190	0.017
CXCL8	117, 116	0.259	0.005	0.206	0.035	150, 150	0.212	0.009	0.209	0.009
IL9	117, 116	0.010	0.91	0.019	0.84	–a	–	–	–	–
IL12	117, 116	−0.013	0.89	−0.046	0.62	150, 150	−0.114	0.166	−0.137	0.095
IFNG	117, 116	0.088	0.34	0.087	0.35	150, 150	0.001	0.990	0.049	0.54
CXCL10	117, 116	0.043	0.65	0.096	0.32	150, 150	−0.085	0.302	−0.083	0.30
CCL4	117, 116	0.023	0.81	0.020	0.83	150, 150	0.100	0.221	0.083	0.29
CCL2	117, 116	0.116	0.21	0.110	0.24	150, 150	−0.025	0.764	−0.023	0.77
CCL11	117, 116	−0.045	0.63	0.025	0.79	–a	–	–	–	–
PDGFB	117, 116	0.117	0.21	0.101	0.28	150, 150	−0.005	0.953	−0.019	0.81

^aNot included in this assay.

^bExcluded from the analysis, as 50 measurements were outside the assay working range or did not meet quality control criteria.

The adjusted correlation coefficients (Beta) were based on multivariable linear regression models that included age (continuous), sex (male, female), tumour location (colon, rectum), Stage (I–II, III–IV), MMR status (proficient, deficient) and BRAF status (wild-type, mutant).